LenioBio and mAIbe have entered into a strategic collaboration designed to accelerate the discovery and experimental validation of next-generation monoclonal antibodies by uniting their complementary capabilities in AI-based design and rapid protein expression. The partnership integrates mAIbe’s AI-driven platform for antibody design and optimization with LenioBio’s ultrafast, scalable cell-free expression technology, enabling a more efficient and data-rich design–build–test cycle.
Also Read: Dassault Aviation, Thales Partners with cortAIx for Sovereign Air Combat AI
LenioBio’s system supports the rapid production of complex antibodies, generating high-quality experimental outputs that directly inform and refine mAIbe’s predictive AI models. This collaborative strategy helps both teams speed up testing of AI-generated antibody candidates. It boosts early validation and speeds up updates between computer predictions and lab results. This partnership closes the lab-in-loop gap. It sets a new standard for speed and flexibility. It also enhances data-driven progress in finding therapeutic antibodies. This positions it to greatly enhance the design and development of next-generation biologics.